Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report

Leukemia Research

Volumn 34, Issue 10, 2010, Pages

  Winkler, J ^a   Rech, D ^a   Kallert, S ^a   Rech, J ^a   Meidenbauer, N ^a   Roesler, W ^a   Mackensen, A ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; DAUNORUBICIN; FLUDARABINE; HLA A ANTIGEN; IDARUBICIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; PREDNISOLONE; RITUXIMAB; SORAFENIB; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; CANCER CHEMOTHERAPY; CASE REPORT; CHROMOSOME 6P; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 6; CHROMOSOME TRANSLOCATION 9; CHRONIC GRAFT VERSUS HOST DISEASE; COLOSTOMY; CYTOGENETICS; DISEASE COURSE; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE LOCUS; GENE MUTATION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE BIOPSY; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOPENIA; LOW DRUG DOSE; MOLECULAR GENETICS; MUCORMYCOSIS; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; FMS-LIKE TYROSINE KINASE 3; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955981259     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.011     Document Type: Letter

References (10)

1. Stussi G., Halter J., Tichelli A., Meyer-Monard S., Buser A.S., Arber C., et al. Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies. Bone Marrow Transplant 2009, 45:103-109.
2. Michallet A.S., Nicolini F., Furst S., Le Q.H., Dubois V., Hayette S., et al. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant 2005, 35:601-608.
3. Levis M., Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol 2005, 82:100-107.
4. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
5. Zhang W., Konopleva M., Shi Y.X., McQueen T., Harris D., Ling X., et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
6. Metzelder S., Wang Y., Wollmer E., Wanzel M., Teichler S., Chaturvedi A., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
7. Crump M., Hedley D., Kamel-Reid S., Leber B., Wells R., Brandwein J., et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010, 51:252-260.
8. Kottaridis P.D., Gale R.E., Frew M.E., Harrison G., Langabeer S.E., Belton A.A., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
9. Safaian N.N., Czibere A., Bruns I., Fenk R., Reinecke P., Dienst A., et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009, 33:348-350.
10. Hipp M.M., Hilf N., Walter S., Werth D., Brauer K.M., Radsak M.P., et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008, 111:5610-5620.